Peripheral nerve sheath tumors, specifically neurofibromas and schwannoma variants, occur both sporadically and in the setting of hereditary conditions, including neurofibromatosis type 1 (NF1), ...

CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

Scientists have discovered the origin of severely disfiguring masses of cells, called neurofibromas, that gradually develop throughout the skin of patients afflicted with Neurofibromatosis 1 (NF1). In ...

Neurofibromatosis type 1 (NF1) is a prevalent genetic disorder caused by germline mutations in the NF1 gene, leading to dysregulation of RAS signalling and predisposing affected individuals to diverse ...

CNW/ - Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib), an oral, selective MEK inhibitor, has been approved in ...

A study published today in PLOS ONE discovered the origin of severely disfiguring masses of cells, called neurofibromas, that gradually develop throughout the skin of patients afflicted with ...

Did you know neurofibromatosis type 1 with plexiform neurofibromas (NF1-PN) is a rare genetic disorder that can cause tumors ...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s largest independent Oncology Pharmacy, has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a ...

Neurofibromatosis (NF1) is a genetic condition which affects one in every 3,000 people. New research shows that a simple blood test for the protein melanoma-inhibitory activity (MIA) could be used to ...

Neurofibromatosis type 1 (NF1) is a rare genetic disorder that affects the nervous system, causing tumors to form on nerves throughout the body. It is also known as Von Recklinghausen disease, named ...

Neurofibromatosis (NF1) is a genetic condition which affects one in every 3,000 people. The severity of symptoms can range from benign ‘café au lait’ patches on the skin, through small tumors under ...